• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Harrow, Inc. - Common Stock (NQ:HROW)

    41.79 +1.78 (+4.45%)
    Streaming Delayed Price Updated: 12:36 PM EDT, Oct 20, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 257,645
    Open 40.70
    Bid (Size) 41.69 (1)
    Ask (Size) 41.88 (1)
    Prev. Close 40.01
    Today's Range 40.31 - 41.89
    52wk Range 20.85 - 57.72
    Shares Outstanding 37,002,136
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Could Harrow's New Sedation Pill Change Millions Of Medical Procedures Forever?
    Harrow, Inc. (NASDAQ: HROW), a U.S.-based provider of ophthalmic disease management solutions, announced on Friday that it has agreed to acquire Melt 
    Via Benzinga
    Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside
    Via Stocktwits

    Performance

    YTD
    +14.3%
    +14.3%
    1 Month
    -5.8%
    -5.8%
    3 Month
    +12.7%
    +12.7%
    6 Month
    +79.8%
    +79.8%
    1 Year
    -25.9%
    -25.9%

    More News

    Read More
    Demystifying Harrow: Insights From 5 Analyst Reviews
    Via Benzinga
    Tesla To Rally Around 4%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    HARROW INC (NASDAQ:HROW) Presents High Growth Momentum and Technical Breakout Opportunity
    Via Chartmill
    A Preview Of Harrow's Earnings
    Via Benzinga
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    Earnings Scheduled For August 11, 2025
    Via Benzinga
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
    From Harrow, Inc.
    Via Business Wire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
    Via Benzinga
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications
    From Harrow, Inc.
    Via Business Wire
    William Blair Bullish On Harrow's High-Margin Branded Eye Drug Strategy
    Via Benzinga
    Assessing Harrow: Insights From 4 Financial Analysts
    Via Benzinga

    Frequently Asked Questions

    Is Harrow, Inc. - Common Stock publicly traded?
    Yes, Harrow, Inc. - Common Stock is publicly traded.
    What exchange does Harrow, Inc. - Common Stock trade on?
    Harrow, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Harrow, Inc. - Common Stock?
    The ticker symbol for Harrow, Inc. - Common Stock is HROW on the Nasdaq Stock Market
    What is the current price of Harrow, Inc. - Common Stock?
    The current price of Harrow, Inc. - Common Stock is 41.79
    When was Harrow, Inc. - Common Stock last traded?
    The last trade of Harrow, Inc. - Common Stock was at 10/20/25 12:36 PM ET
    What is the market capitalization of Harrow, Inc. - Common Stock?
    The market capitalization of Harrow, Inc. - Common Stock is 1.55B
    How many shares of Harrow, Inc. - Common Stock are outstanding?
    Harrow, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.